149 articles
Amphastar (1795) announced astonishing financial results, with February 2026 monthly revenue soaring to NT$2.238 billion, representing a significant year-on-year increase of 131.5%. As a leading generic drug manufacturer in the Asia-Pacific region, this strong performance is likely driven by the success of high-value products such as addiction treatment drugs in overseas markets.
China Chemical & Pharmaceutical Co. (1762) announced that its February 2026 revenue reached NT$103 million, a significant increase of 161.3% compared to the same period last year. The explosive growth in revenue for this biomedical raw material pharmaceutical company may be attributed to concentrated shipments of specific drug orders.
Visco Technologies Co., Ltd. reported a basic EPS of NT4.08 for Q4 2025. The company achieved operating revenue of NT.223 billion and a net profit after tax of NTbash.887 billion.
PharmaEssentia, a new drug development company, announced that its revenue for February 2026 reached 1.60 billion, a year-over-year increase of 56.7%. This strong performance is primarily attributed to the sales of its new drug for treating polycythemia vera, highlighting its success in the biotechnology and healthcare market.
GNT Biotech (6885) announced its financial report for February 2026. The company's revenue for the month was 632 thousand TWD (0.01 hundred million TWD), an increase of 1758.8% compared to the same period last year. GNT Biotech is a company specializing in the biotech and healthcare industry.
Scinopharm (1789) announced its February 2026 monthly revenue of NT$207 million, a significant year-on-year increase of 26.3%. As a globally important active pharmaceutical ingredient (API) supplier, this revenue growth reflects the stable increase in customer orders in high-barrier fields such as cancer drugs.
HoKang Biotech (1783) announced its February 2026 revenue of NT$0.48 billion, achieving a year-on-year growth of 20.9%. The company, part of the biotechnology and medical industry, specializes in collagen and hyaluronic acid medical materials. This revenue increase reflects strong demand in the medical aesthetics and orthopedics markets.
Bangrui Biotech Co., Ltd. reported a basic EPS of NT$ 4.13 for Q4 2025. The company achieved operating revenue of NT$ 306 million and a net income after tax of NT$ 103 million.
Pegavision Corporation (stock code: 6491), a biotechnology and medical care company, reported a basic EPS of NT0.87 for Q4 2025. The company's revenue reached NT.039 billion, with a net income after tax of NT.650 billion.
PharmaEssentia Corp. announced robust financial performance for Q4 2025, achieving a basic EPS of 13.64 NTD. The company reported operating revenue of 15.635 billion NTD and a net income after tax of 5.045 billion NTD.
Bora Pharmaceuticals reported a basic EPS of NT3.90, revenue of NT9.014 billion, and net income after tax of NT.046 billion for Q4 2025.
Ching Tsung Health Co., Ltd. announced its Q4 2025 financial results, reporting a basic earnings per share of 1.39 NTD. The company achieved an operating revenue of 1.122 billion NTD and a net income after tax of 0.094 billion NTD.
Lotus Pharmaceutical Co., Ltd. (1795) announced its fourth quarter 2025 financial results, reporting a basic earnings per share (EPS) of NT$18.14. The company achieved quarterly revenue of NT$20.509 billion and a net profit after tax of NT$4.720 billion, solidifying its position as a leading company in Taiwan's biotechnology and healthcare sector.
Asiachem (4119), a major active pharmaceutical ingredient (API) manufacturer, announced its February 2026 revenue, showing strong growth momentum. The company's single-month revenue reached NT$119 million, a significant year-on-year increase of 39.9%. This excellent performance is attributed to the launch of new production capacity and the recovery of orders for its main product lines, indicating that the company has emerged from its slump.
Syngen Biotech (6794) has released its financial report for February 2026. The company's revenue for the month was 2,630 thousand NTD (0.03 billion NTD), an increase of 186.2% compared to the same period last year. Syngen Biotech is a company specializing in the biotechnology and healthcare industry.
Grape King (1707) announced its February 2026 monthly revenue of NT$626 million. The renowned health food giant in the biomedical industry saw a slight 1.3% decline in revenue compared to the same period last year, demonstrating its continued solid operational foundation amidst fierce market competition.
Tanvex-KY has announced its impressive revenue report for February 2026. The company's revenue for the month was 0.23 billion, a surge of 218.7% compared to the same period last year. This figure indicates that the biotechnology and healthcare company has made significant progress in the biosimilar market.
Sheng Ta (1720) released its financial report, showing that its February 2026 monthly revenue was NT$466 million, a 16.4% decrease compared to the same period last year. As a pharmaceutical company in the biotechnology and healthcare industry, its revenue performance may be affected by drug shipment schedules and market demand.
Maywufa (1731) announced its February 2026 revenue of NT$128 million. This company, spanning hair care and biomedical industries, reported a 3.7% year-on-year revenue increase, demonstrating its stable brand power and channel management in the consumer market.
Rayz Technologies Co., Ltd. reported a basic EPS of NT$ 3.84 for Q4 2025, with operating revenue reaching NT$ 2.294 billion and net profit after tax at NT$ 160 million.
Yonghong International Biotechnology Co., Ltd. reported a basic EPS of NT.82 for Q4 2025. The company's operating revenue reached NT.416 billion, with a net profit after tax of NT29 million.
Washin Technology (4771) reported a basic EPS of NT2.71 for Q4 2025, with operating revenue reaching NT.487 billion and net income after tax at NT08 million.
Herong Technology Co., Ltd. reported a basic EPS of -3.31 NTD and a net loss of 482 million NTD for Q4 2025. The company's operating revenue for the quarter was 10 million NTD.
Aipass Biotech (Company Code: 6918) reported strong financial results for Q4 2025, with basic EPS of NT.16, revenue of NT36 million, and net profit after tax of NT70 million.
PBF Inc. (1760) announced its February 2026 monthly revenue as NT$233 million, a year-on-year decrease of 4.5%. The biotechnology and healthcare company, which spans pharmaceuticals, health products, and cosmetics, saw its revenue performance influenced by the combined effects of sales across various product lines and the effectiveness of market promotions.
Wuding (1733) announced its February 2026 monthly revenue was NT$178 million, a 12.0% decrease compared to the same period last year. As a leading biotech and medical industry player specializing in blood glucose monitoring systems, its revenue performance is related to changes in demand in the global diabetes care market.
Heart & Soul Medical Electronics Co., Ltd. reported a basic EPS of -3.92 NTD for Q4 2025. The company's operating revenue was 100 million NTD, with a net loss after tax of 126 million NTD.
Huaan Medical Co., Ltd. reported an operating revenue of 0.08 billion NTD and a net loss of 2.58 billion NTD for Q4 2025, resulting in a basic EPS of -2.92 NTD.
Cheng Yeh Medical (4164), a leading provider of radiotherapy oncology equipment and services, announced strong revenue performance for February 2026. The company's monthly revenue reached NT$269 million, representing a year-on-year increase of 22.8%. This growth reflects the stable recognition of equipment installation and service contracts with hospital clients, demonstrating its leadership position in the high-end medical market.
EirGenix, Inc. has released its financial report for February 2026, posting a monthly revenue of NT$85 million, which represents a 100.6% growth compared to the same period last year. This figure indicates the biotechnology and medical care company's strong expansion in its CDMO business.
Wangjun, a disposable contact lens manufacturer, announced its February 2026 revenue of NT$315 million, marking a year-on-year increase of 21.3%. This strong growth reflects robust OEM order demand from the Japanese and mainland Chinese markets, as well as contributions from new product shipments.
Nankuang announced its revenue report for February 2026, revealing that its monthly revenue was NT$156 million, a decrease of 20.0% compared to the same period last year. This data reflects the company's financial performance within the biotechnology and medical industry during the reporting period, offering the market a reference indicator of its operational status.
Kwang Tai Medicinal Co., Ltd. reported Q4 2025 earnings per share (EPS) of NT$8.22, with revenue of NT$10.252 billion and net profit after tax of NT$1.861 billion.
TaiDoc Technology (4736) announced its Q4 2025 financial results, reporting a basic EPS of NT5.12. The company's operating revenue reached NT.204 billion, with a net income after tax of NT.463 billion.
PURE BioMedicine Co., Ltd. reported an operating revenue of 31 million NTD and a net loss of 453 million NTD for Q4 2025, resulting in a basic EPS of -7.23 NTD.
Jinwanlin Enterprise Co., Ltd. reported a basic EPS of -2.41 NTD and a net loss of 148 million NTD for Q4 2025. The company's operating revenue for the quarter was 549 million NTD.
SciClone Biomedical Technology Co., Ltd. reported an operating revenue of 0.30 billion NTD and a net loss of 1.15 billion NTD for Q4 2025, with basic EPS at -1.89 NTD.
Tai-Shin Pharmaceutical Co., Ltd. reported a basic EPS of -0.55 NTD and an operating revenue of 0.09 billion NTD for Q4 2025, with a net loss after tax of 0.84 billion NTD.
Jin Hong Technology Co., Ltd. (Company Code: 6796), operating in the biotechnology and medical industry, reported a basic EPS of NTbash.20 for Q4 2025. The company achieved operating revenue of NT61 million and a net income after tax of NT million.
Polaris Group-KY announced its February 2026 revenue reached NT$17 million, a significant year-over-year increase of 322.9%. The biotechnology and healthcare company is showing strong growth momentum, with revenue performance significantly outpacing the same period last year.
Shin Ho (1734) announced its February 2026 monthly revenue as NT$196 million. This biotechnology and healthcare company, which operates in pharmaceuticals, health products, and cosmetics, saw a 17.4% year-over-year decrease in revenue, reflecting changes and challenges in the pharmaceutical market.
KANBO Biotech (6919), a biotechnology and medical care company, reported a basic EPS of -0.23 NTD for Q4 2025, with operating revenue of 0.038 billion NTD and a net loss of 0.352 billion NTD after tax.
Taiyao Chemical Co., Ltd. announced its Q4 2025 financial results, reporting a basic earnings per share of NT.67. The company achieved an operating revenue of NT.851 billion and a net profit after tax of NT96 million.
Quanfa Biotechnology Co., Ltd. reported a basic earnings per share of -3.32 NTD, operating revenue of 0.05 billion NTD, and a net loss after tax of 4.51 billion NTD for Q4 2025.
Synergetics announced its February 2026 revenue figures. The biotech and medical company reported a monthly revenue of NT$106 million, a year-on-year increase of 10.8%. As a supplier of blood glucose monitoring systems, this growth reflects stable market demand for its products.
Wellell Biotech Co., Ltd. (stock code 1783) reported its financial results for the fourth quarter of 2025. The company posted an earnings per share (EPS) of NT$2.96 for the quarter. Revenue reached NT$812 million, with a net profit after tax of NT$265 million. Wellell Biotech operates in the biotechnology and medical industry, focusing on collagen and hyaluronic acid.
BaoLing-FuJin Biotech Co., Ltd. (Stock Code: 1760) has released its financial results for the fourth quarter of 2025. The company reported basic earnings per share (EPS) of NT$2.22 for the quarter. Quarterly operating revenue reached NT$2.063 billion, with a net profit after tax of NT$190 million. BaoLing-FuJin continues its development in the biotechnology and medical sector.
Ascent PharmaTech Co., Ltd. reported a basic EPS of NTbash.90 for Q4 2025. The company's operating revenue reached NT.344 billion, with a net income after tax of NTbash.107 billion.
Synergetics Biomedical Investment Holdings Co., Ltd. announced its Q4 2025 financial results, reporting a basic EPS of 1.00 NTD, operating revenue of 4.398 billion NTD, and a net income after tax of 226 million NTD.
Cosmetic Science Biotech Co., Ltd. (1786) reported its operating results for the fourth quarter of 2025. The company announced a basic earnings per share (EPS) of NT$2.24 for the quarter. Revenue reached NT$887 million, with a net profit after tax of NT$162 million. Cosmetic Science Biotech operates within the biotechnology and medical industry.
Pelle Life Sciences-Emerging (6949) has announced its financial report for February 2026. The company's revenue for the month was 1,971 thousand (0.02 hundred million), a 61.2% increase compared to the same month last year. Pelle Life Sciences-Emerging is a company specializing in the biotechnology and healthcare industry.
Syncmold (6934) has released its financial report for February 2026. The company's revenue for the month was 18 thousand dollars (0.00 billion), a decrease of 91.2% compared to the same period last year. Syncmold is a company specializing in the biotechnology and medical industry.
Applied BioCode (ABC-KY) announced its February 2026 revenue was NT$72 million, a significant year-over-year increase of 81.3%. The biotechnology and medical company is showing strong growth momentum, driven by the strong performance of its multiplex molecular diagnostics platform business.
Global Bio-Chem-KY announced its operational results for February 2026. The company, operating in the biomedical industry, achieved monthly revenue of NT$174 million, marking a 10.8% increase compared to the same period last year, indicating a continuous expansion trend in its business.
TLC (6838) announced its financial report for February 2026. The company's revenue for the month was 1,308 thousand (0.01 billion), an increase of 120.2% compared to the same period last year. TLC is a company focused on the biotechnology and medical care industry.
Pegavision Corporation's February 2026 revenue report indicates a monthly revenue of 557 million, a 6.0% increase compared to the same period last year. The contact lens manufacturer, part of the biotechnology and medical industry, continues to demonstrate stable growth in the consumer market.
Bio-medical enterprise ABEO Company announced its February 2026 revenue data. The company's revenue for the month was NT$188 million, achieving a year-on-year growth of 10.6%, indicating stable development in the market for products such as medical air mattresses and respiratory therapy devices.
Mewah Holdings Limited (stock code: 1731) announced its financial results for the fourth quarter of 2025. The company reported basic earnings per share (EPS) of NT$1.36, with revenue of NT$1.584 billion and net profit after tax of NT$181 million.
Standard Chemical Pharmaceutical Co., Ltd. (Stock Code: 1720) announced its financial report for the fourth quarter of 2025. The company's operating revenue for the quarter was NT$7.023 billion, with a net profit after tax of NT$1.256 billion, and basic earnings per share of NT$5.19. The company belongs to the biotechnology and medical industry.
TaiFu Biopharmaceutical (Company Code: 6541) reported a basic EPS of -6.13 NTD for Q4 2025. The company's operating revenue was 401 million NTD, with a net loss after tax of 1.5 billion NTD.
Luolifen Holdings Co., Ltd. (Company Code: 6666), operating in the Biotechnology and Medical Industry, announced its Q4 2025 financial results. The company reported a basic earnings per share of NTD 2.42, with operating revenue reaching NTD 1.113 billion and net income after tax at NTD 108 million.
Polaris Pharmaceuticals, Inc. (stock code: 6550) reported a basic EPS of -5.10 NTD, revenue of 0.41 billion NTD, and a net loss after tax of 3.945 billion NTD for the fourth quarter of 2025.
Lih-Feng Co., Ltd. (Company Code: 4137) reported a basic EPS of NT$ 7.13 for Q4 2025. The company's operating revenue reached NT$ 3.878 billion, with a net income after tax of NT$ 0.588 billion.
Joho Biotech Co., Ltd. announced its Q4 2025 financial results, reporting a basic EPS of 4.51 NTD and operating revenue of 1.819 billion NTD.
White (4108), a biomedical company focused on new drug development, announced its revenue for February 2026. The company's monthly revenue was NT$0.09 billion, representing a 5.0% increase compared to the same period last year. This steady growth reflects the stable sales performance of its products in the market, including "White Blood Treasure."
Wading Biotechnology Co., Ltd. (stock code 1733) announced its financial results for the fourth quarter of 2025. The company reported basic earnings per share (EPS) of NT$1.63 for the quarter. Quarterly operating revenue reached NT$1.945 billion, with a net profit after tax of NT$163 million. Wading Biotechnology specializes in the biotechnology and medical industry.
Sino-American Pharmaceutical Co., Ltd. (1734) reported its Q4 2025 financial results, with basic earnings per share (EPS) at NT$1.92. The company's revenue was NT$3.371 billion, and net profit after tax was NT$354 million.
Nang Kwang Chemical Pharmaceutical Co., Ltd. (Stock Code: 1752) reported its financial results for the fourth quarter of 2025. The company's operating revenue for the quarter was NT$2.162 billion, with a net profit after tax of NT$244 million, resulting in basic earnings per share of NT$2.42. The company belongs to the biotechnology and healthcare industry.
King's Group Biotech Co., Ltd. announced its Q4 2025 financial results, reporting a basic EPS of 0.66 NTD. The company achieved an operating revenue of 401 million NTD and a net profit after tax of 48 million NTD.
TaiCoo Biologics Inc. reported an operating revenue of NT.005 billion and a net loss of NT61 million for Q4 2025, with basic EPS at -NT.51.
Guangli Biotechnology Holdings Co., Ltd. reported an operating revenue of 377 million NTD and a net loss after tax of 193 million NTD for Q4 2025, resulting in a basic EPS of -2.07 NTD.
Adimmune Corporation reported a basic EPS of -0.57 NTD and a net loss of 330 million NTD for Q4 2025, despite achieving operating revenue of 1.402 billion NTD.
Visco Technologies announced its financial report for February 2026, with monthly revenue reaching NT$379 million, an 11.6% increase compared to the same period last year. As a major global manufacturer of silicone hydrogel contact lenses, this figure indicates stable business growth.
Biotechnology and medical device giant TaiDoc Technology announced its February 2026 revenue of NT$262 million, a year-over-year decrease of 15.6%. This decline is primarily due to a high comparison base from the previous demand for COVID-19 test kits, with operations now returning to regular products such as blood glucose meters.
Waan Medical announced its financial data for February 2026, with a monthly revenue of NT$270,000 (approximately NT$0.00 billion), an 8.5% decrease compared to the same period last year. This figure reflects the operational and financial status of the biotechnology company, which is in the new drug development phase.
Jiayi (4104), a medical equipment distribution and service provider, announced its February 2026 monthly revenue report. The company's single-month revenue was NT$696 million, a slight decrease of 3.4% compared to the same period last year. This data indicates that the company's operations in core business areas such as hemodialysis and medical aesthetics remain largely stable.
Raydium (6861) has released its financial report for February 2026. The company's revenue for the month was 260,053 thousand yuan (260 million), a 44.0% increase compared to the same period last year. Raydium is a company specializing in the biotechnology and healthcare industry.
Hwa Kuang Biotech Co., Ltd. reported a net loss of NThBc179 million and basic EPS of NThBc2.68 for Q4 2025, with operating revenue reaching NT.839 billion.
Loreley-KY has announced its revenue for February 2026, reporting NT$58 million, a decrease of 12.5% compared to the same period last year. This financial performance reflects the market sales condition of the beauty and skincare company during the reporting period.
Holontech announced its revenue for February 2026 was 190 thousand NTD (approximately 0.00 billion NTD). Year-on-year comparison data was not provided. This is the company's latest financial data in the biotechnology and medical industry, reflecting its current operational status.
GeneFirst-Emerging announced its revenue for February 2026 reached NT$36 million, a 12.0% increase year-over-year. The revenue figures for the biotechnology company, which specializes in precision medicine, demonstrate stable growth in its genetic testing services business.
AppliedChem-CREATE released its revenue report for February 2026, recording NT$273 million, a 2.1% increase compared to the same period last year. As a company specializing in the agricultural biotechnology sector, this figure indicates a stable growth trend in its business during the reporting period.
Taiyao Chemical, a major manufacturer of active pharmaceutical ingredients (APIs), announced its February 2026 monthly revenue of NT$233 million, a 20.5% year-on-year decrease. This figure reflects changes in customer order patterns and product mix. The company has long focused on areas such as cholesterol reduction and Vitamin D.
LaFang-KY (4137), which owns the "Chlitina" beauty chain, announced its February 2026 monthly revenue. The company's single-month revenue was NT$196 million, a year-on-year decrease of 32.9%. This significant decline may be attributed to the sluggish consumer market in Greater China and seasonal factors.
Bonraybio-GISA (6955) announced its financial report for February 2026. The company's revenue for the month was 26,906 thousand TWD (approx. 27 million TWD), a 13.0% increase compared to the same period last year. Bonraybio-GISA is a company specializing in the biotechnology and healthcare industry.
Kuang Li-KY released its February 2026 financial report, showing a single-month revenue of NT$0.022 billion, a 15.6% decrease compared to the same period last year. The company is a participant in the biotechnology and healthcare industry, and this data reflects its operating conditions during the reporting period.
Taiwan's major pharmaceutical manufacturer, Yung Shin (3705), announced its financial data for February 2026. The company's monthly revenue was NT$524 million, a 16.7% decrease compared to the same period last year. This decline may be related to seasonal factors in pharmaceutical sales or adjustments in national health insurance drug pricing policies, reflecting the operational challenges within the pharmaceutical industry.
Bora Pharmaceuticals released its revenue report for February 2026, posting NT$1.326 billion, a 23.2% decrease year-over-year. As a company specializing in pharmaceutical CDMO within the biotech and healthcare industry, this financial performance reflects the cyclical fluctuations of the sector.
Chia-Yi Health Care Co., Ltd. reported a basic EPS of NT.70 for Q4 2025. The company achieved operating revenue of NT.789 billion and a net income after tax of NT66 million.
Jourdeness (佐登-KY), a beauty and biotechnology medical service provider, announced its February 2026 revenue of NT$138 million. This figure represents a 22.9% year-on-year decrease, which may reflect changes in the consumer market or a period of strategic adjustment for the company.
APIS (6918) has released its financial report for February 2026. The company's revenue for the month was 74,229 thousand yuan (0.74 hundred million yuan), an increase of 6.5% compared to the same period last year. APIS is a company specializing in the biotechnology and medical industry.
Adimmune Corporation (4142), a vaccine and biopharmaceutical developer and manufacturer, announced its February 2026 revenue. The company's monthly revenue was NT$0.06 billion, a 19.7% decrease compared to the same period last year. This figure reflects seasonal factors, as the peak flu vaccine shipping season has passed, leading to a traditional off-peak season for revenue.
Co-Yea Biotech (1786), a biotechnology and medical enterprise, announced its February 2026 revenue report. The company's revenue for the month was NT$ 0.55 billion (NT$ 55,099 thousand), marking a slight year-on-year increase of 0.1%, maintaining relatively stable operational performance.
All Cosmos Bio-Tech Holding Corporation (Company Code: 4148) reported its Q4 2025 financial results. The company achieved a basic EPS of NTD 2.28, with revenue reaching NTD 2.949 billion and net income after tax at NTD 206 million.
Yung Hsin International Investment Holdings Co., Ltd. announced its Q4 2025 financial results, reporting a basic EPS of NT$ 3.31, operating revenue of NT$ 8.376 billion, and net income after tax of NT$ 948 million.
AboCom Corporation (Company Code: 4106), a biotechnology and medical industry company, announced its Q4 2025 financial results, reporting a basic EPS of NT.20, operating revenue of NT.404 billion, and net income after tax of NTbash.122 billion.
China Chemical Holdings Co., Ltd. reported a basic EPS of 2.39 NTD for Q4 2025. The company's operating revenue reached 8.57 billion NTD, with a net profit after tax of 300 million NTD.
Sigrity Optoelectronics Co., Ltd. (Code: 4155) reported NT$ 1.556 billion in revenue and NT$ 0.097 billion in net income after tax for Q4 2025, with basic EPS of NT$ 0.58.
Huagung (stock code: 4737) announced its revenue report for February 2026. The revenue for the month was NT$111 million, a decrease of 28.9% compared to the same period last year. The company belongs to the biotechnology and medical industry.
Chingsung Healthcare (6931) has announced its financial report for February 2026. The company's revenue for the month was 89,639 thousand yuan (90 million yuan), an increase of 6.4% compared to the same period last year. Chingsung Healthcare is a company specializing in the biotechnology and medical industry.
Jin-Hong (6796) has announced its financial report for February 2026. The company's revenue for the month was 44,509 thousand dollars (0.045 billion), an 8.1% increase compared to the same period last year. Jin-Hong is a company specializing in the biotechnology and medical industry.
Genmont Biotechnology announced its February 2026 monthly revenue was NT$0.16 billion, a year-on-year decrease of 35.5%. This biomedical company specializes in probiotic products, and its monthly revenue data reflects the current market sales conditions and challenges it faces.
Canopy* (6919) has announced its financial report for February 2026. The company's revenue for the month was 0 thousand dollars (0.00 billion dollars), with the year-over-year percentage change not provided. Canopy* is a company focused on the biotechnology and medical industry.
Yung Hung Biotech (6936) has announced its financial results for February 2026. The company's revenue for the month was 92,334 thousand TWD (NT$92 million), an 11.7% decrease compared to the same period last year. Yung Hung Biotech is a company specializing in the biotechnology and healthcare industry.
China Chemical Holdings announced its February 2026 monthly revenue. As an enterprise in the biotech and medical sector, its revenue for the month was NT$622 million, a decrease of 7.2% compared to the same month last year. This data serves as one of the reference indicators for evaluating the company's operations during the quarter.
White Biotech New Drug Co., Ltd. reported a basic earnings per share of -0.29 NTD, operating revenue of 135 million NTD, and a net loss after tax of 110 million NTD for Q4 2025.
Anorfa Co. announced its February 2026 revenue report. The biomedical company's revenue for the month was NT$0.28 billion, a decrease of 12.4% compared to the same period last year. This financial data provides a snapshot of the company's recent operational status.
Taiwan Biotech Company (TWSE: 1789) announced its fourth quarter 2025 financial results, reporting basic earnings per share (EPS) of NT$0.17. The company's revenue for the quarter reached NT$3.163 billion, with a net profit after tax of NT$137 million. Taiwan Biotech operates within the biotechnology and healthcare industry, focusing on active pharmaceutical ingredients (APIs).
Arnorfa Biotech (Company Code: 4133) reported an operating revenue of 351 million NTD and a net loss after tax of 1 million NTD for Q4 2025. The basic earnings per share were -0.02 NTD.
Jordanes Group Co., Ltd. reported an operating revenue of NTD 2.309 billion and a net loss after tax of NTD 0.094 billion for Q4 2025. Basic earnings per share were -NTD 1.59.
China Chemical Synthesis Biotechnology Co., Ltd. (1762) reported its Q4 2025 financial results, with basic earnings per share (EPS) at -NT$4.39. The company's revenue was NT$805 million, and net loss after tax was NT$244 million.
Tai-Tsung's monthly revenue for March 2026 was NT$62 million, an increase of 9.1% year-over-year. The company is classified in the biotechnology and medical care industry.
TaiDoc Technology announced its monthly revenue for March 2026 was NT$444 million, a staggering 48.7% increase year-over-year. The company operates in the Biotechnology and Medical Care industry.
CHENG-HE Medical's monthly revenue for March 2026 was NT$577 million, an increase of 3.4% year-over-year. The company is classified in the biotechnology and medical care industry.
Hsin-Yin's monthly revenue for March 2026 was NT$146 million, a decrease of 10.4% year-over-year. The company is classified in the biotechnology and medical care industry.
VISCO, a biotechnology and medical care company, announced that its monthly revenue for March 2026 reached NT$348 million, an 18.2% increase compared to the same month last year, indicating steady growth.
Jourden-KY's monthly revenue for March 2026 was NT$209 million, a slight decrease of 0.5% year-over-year. The company is classified in the biotechnology and medical care industry.
All Cosmos Bio-Tech's monthly revenue for March 2026 was NT$214 million, a decrease of 18.6% year-over-year. The company is classified in the biotechnology and medical care industry.
Adimmune's revenue for March 2026 was NT$65 million, a staggering increase of +2102.7% year-over-year. The company is in the Biotechnology and Medical Care industry.
Formosa Laboratories announced its monthly revenue for March 2026 was NT$456 million, a 6.0% decrease year-over-year. The company operates in the Biotechnology and Medical Care industry.
Excelsior Medical's revenue for March 2026 was NT$842 million, an increase of 15.1% year-over-year. The company operates in the Biotechnology and Medical Care industry.
Bionime Corp. announced its monthly revenue for March 2026 was NT$167 million, a 4.7% increase year-over-year. The company operates in the Biotechnology and Medical Care industry.
APEX's revenue for March 2026 was NT$208 million, an increase of 7.0% year-over-year. The company is in the Biotechnology and Medical Care industry.
Chung Hwa Bio (stock code: 1762) announced its March 2026 monthly revenue of 131.435 million JPY, a significant 108.9% increase compared to the same period last year. This strong performance highlights the company's robust growth within the biotechnology and medical sector.
My-Wow announced its monthly revenue for March 2026 reached NT$137 million, marking a significant year-on-year increase of 15.1%. This strong performance highlights the company's robust growth within the biotechnology and medical industry.
Wuding announced its monthly revenue for March 2026 was NT$141 million, representing a significant year-on-year decrease of 24.1%. This data provides key insights into the company's performance within the biotech and medical industry.
BaoLing FuJin reported March 2026 revenue of 150 million JPY, a 17.1% increase year-over-year. This growth in the biotechnology and healthcare sector highlights the company's expanding market presence.
PharmaEssentia announced its March 2026 monthly revenue reached NT$1.94 billion, marking a substantial year-on-year increase of 64.4%. This strong performance highlights the company's robust growth within the biotechnology and medical industry.
WAKANSE announced its revenue for March 2026, reaching 69.939 million yen (approximately 0.70 hundred million yen), a slight increase of 0.1% compared to the same period last year. The company operates in the biotechnology and healthcare industry.
Megalith (1795) reported its March 2026 revenue at NT$4.354 billion (NT$4,354,277 thousand), marking a substantial year-over-year increase of 173.6%. This strong performance in the biotechnology and healthcare sector highlights the company's significant growth.
Huaan reported March 2026 revenue of 0.01 billion yuan, a significant 50.2% increase year-on-year. This growth highlights the company's strong performance and expansion within the biotechnology and healthcare industry.
Shengda (stock code: 1720) reported its March 2026 revenue at NT$570.224 million, marking a 2.8% increase compared to the same period last year. This growth in the biotechnology and medical sector highlights the company's steady performance.
Lih-Feng-KY's revenue for March 2026 was NT$344 million, an increase of 3.7% year-over-year. The company is in the Biotechnology and Medical Care industry.
PhytoHealth's revenue for March 2026 was NT$10 million, a decrease of 21.4% year-over-year. The company is in the Biotechnology and Medical Care industry.
CCPC Holding's revenue for March 2026 was NT$728 million, an increase of 0.1% year-over-year. The company is in the Biotechnology and Medical Care industry.
SCI Pharmtech's revenue for March 2026 was NT$128 million, a decrease of 24.4% year-over-year. The company is in the Biotechnology and Medical Care industry.
TaiFu-KY announced its monthly revenue for March 2026 reached NT$0.92 billion, marking a substantial year-over-year increase of 134.7%. This strong performance highlights the company's robust growth in the biotechnology and medical industry and sets positive expectations for future results.
Shenlong announced its March 2026 monthly revenue of 325 million yuan, marking a 3.4% increase compared to the same period last year. This performance highlights the company's steady growth within the biotechnology and healthcare sector.
Luo Li Fen-KY recorded revenue of 102 million yuan in March 2026, a decrease of 14.8% compared to the same period last year. The company operates in the biotechnology and healthcare industry.
Abnova's revenue for March 2026 was NT$34 million, a decrease of 4.1% year-over-year. The company is in the Biotechnology and Medical Care industry.
GenMont (3164), in the biotechnology and medical care industry, announced its monthly revenue for March 2026. The revenue was 38 million TWD, a year-on-year decrease of -12.6%.
Nanguang announced its monthly revenue for March 2026 reached NT$162 million, a 14.2% decrease compared to the same period last year. The company operates in the biotechnology and healthcare sector.
Zhenghan-Chuang announced its monthly revenue for March 2026 reached NT$377 million, marking a 2.5% increase compared to the same month last year. This indicates stable growth for the company in the biotechnology and medical industry.
Yung Shin Pharmaceutical announced its March 2026 monthly revenue was NT$620 million, a sharp decrease of 23.7% year-over-year. This indicates challenges in the biotechnology and medical care industry.
K.K. K.K. announced its March 2026 revenue of 25.988 million yuan, a decrease of 32.1% year-on-year. The company, operating in the biotechnology and healthcare sector, may be experiencing market fluctuations.
ABC-KY reported its March 2026 revenue at 66.022 million yen (0.066 billion yen), marking a significant 72.5% increase compared to the same period last year. This performance highlights strong growth within the biotechnology and healthcare sector.
Boray (Stock Code: 6472), a company in the biotech and healthcare sector, reported its March 2026 revenue at NT$1.528 billion, marking a 6.3% increase compared to the same period last year. This growth underscores the company's strong performance and expanding presence in the industry.
Keyen announced its March 2026 monthly revenue of 74.827 million yuan, marking a 0.8% increase compared to the same period last year. Operating within the biotechnology and healthcare sector, this performance indicates steady growth and market resilience.
TaiGen Biotechnology announced its March 2026 revenue of 115 million yuan, marking a significant 28.2% increase compared to the same period last year. This strong performance in the biotechnology and healthcare sector highlights the company's robust growth and expanding market presence.